Cargando…
Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund’s adjuvant model of orofacial pain
BACKGROUND: The neurochemical background of the evolution of headache disorders, still remains partially undiscovered. Accordingly, our aim was to further explore the neurochemical profile of Complete Freund’s adjuvant (CFA)-induced orofacial pain, involving finding the shift point regarding small m...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175490/ https://www.ncbi.nlm.nih.gov/pubmed/32316909 http://dx.doi.org/10.1186/s10194-020-01105-6 |
_version_ | 1783524841475801088 |
---|---|
author | Cseh, Edina K. Veres, Gábor Körtési, Tamás Polyák, Helga Nánási, Nikolett Tajti, János Párdutz, Árpád Klivényi, Péter Vécsei, László Zádori, Dénes |
author_facet | Cseh, Edina K. Veres, Gábor Körtési, Tamás Polyák, Helga Nánási, Nikolett Tajti, János Párdutz, Árpád Klivényi, Péter Vécsei, László Zádori, Dénes |
author_sort | Cseh, Edina K. |
collection | PubMed |
description | BACKGROUND: The neurochemical background of the evolution of headache disorders, still remains partially undiscovered. Accordingly, our aim was to further explore the neurochemical profile of Complete Freund’s adjuvant (CFA)-induced orofacial pain, involving finding the shift point regarding small molecule neurotransmitter concentrations changes vs. that of the previously characterized headache-related neuropeptides. The investigated neurotransmitters consisted of glutamate, γ-aminobutyric acid, noradrenalin and serotonin. Furthermore, in light of its influence on glutamatergic neurotransmission, we measured the level of kynurenic acid (KYNA) and its precursors in the kynurenine (KYN) pathway (KP) of tryptophan metabolism. METHODS: The effect of CFA was evaluated in male Sprague Dawley rats. Animals were injected with CFA (1 mg/ml, 50 μl/animal) into the right whisker pad. We applied high-performance liquid chromatography to determine the concentrations of the above-mentioned compounds from the trigeminal nucleus caudalis (TNC) and somatosensory cortex (ssCX) of rats. Furthermore, we measured some of these metabolites from the cerebrospinal fluid and plasma as well. Afterwards, we carried out permutation t-tests as post hoc analysis for pairwise comparison. RESULTS: Our results demonstrated that 24 h after CFA treatment, the level of glutamate, KYNA and that of its precursor, KYN was still elevated in the TNC, all diminishing by 48 h. In the ssCX, significant concentration increases of KYNA and serotonin were found. CONCLUSION: This is the first study assessing neurotransmitter changes in the TNC and ssCX following CFA treatment, confirming the dominant role of glutamate in early pain processing and a compensatory elevation of KYNA with anti-glutamatergic properties. Furthermore, the current findings draw attention to the limited time interval where medications can target the glutamatergic pathways. |
format | Online Article Text |
id | pubmed-7175490 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Milan |
record_format | MEDLINE/PubMed |
spelling | pubmed-71754902020-04-24 Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund’s adjuvant model of orofacial pain Cseh, Edina K. Veres, Gábor Körtési, Tamás Polyák, Helga Nánási, Nikolett Tajti, János Párdutz, Árpád Klivényi, Péter Vécsei, László Zádori, Dénes J Headache Pain Research Article BACKGROUND: The neurochemical background of the evolution of headache disorders, still remains partially undiscovered. Accordingly, our aim was to further explore the neurochemical profile of Complete Freund’s adjuvant (CFA)-induced orofacial pain, involving finding the shift point regarding small molecule neurotransmitter concentrations changes vs. that of the previously characterized headache-related neuropeptides. The investigated neurotransmitters consisted of glutamate, γ-aminobutyric acid, noradrenalin and serotonin. Furthermore, in light of its influence on glutamatergic neurotransmission, we measured the level of kynurenic acid (KYNA) and its precursors in the kynurenine (KYN) pathway (KP) of tryptophan metabolism. METHODS: The effect of CFA was evaluated in male Sprague Dawley rats. Animals were injected with CFA (1 mg/ml, 50 μl/animal) into the right whisker pad. We applied high-performance liquid chromatography to determine the concentrations of the above-mentioned compounds from the trigeminal nucleus caudalis (TNC) and somatosensory cortex (ssCX) of rats. Furthermore, we measured some of these metabolites from the cerebrospinal fluid and plasma as well. Afterwards, we carried out permutation t-tests as post hoc analysis for pairwise comparison. RESULTS: Our results demonstrated that 24 h after CFA treatment, the level of glutamate, KYNA and that of its precursor, KYN was still elevated in the TNC, all diminishing by 48 h. In the ssCX, significant concentration increases of KYNA and serotonin were found. CONCLUSION: This is the first study assessing neurotransmitter changes in the TNC and ssCX following CFA treatment, confirming the dominant role of glutamate in early pain processing and a compensatory elevation of KYNA with anti-glutamatergic properties. Furthermore, the current findings draw attention to the limited time interval where medications can target the glutamatergic pathways. Springer Milan 2020-04-21 /pmc/articles/PMC7175490/ /pubmed/32316909 http://dx.doi.org/10.1186/s10194-020-01105-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Cseh, Edina K. Veres, Gábor Körtési, Tamás Polyák, Helga Nánási, Nikolett Tajti, János Párdutz, Árpád Klivényi, Péter Vécsei, László Zádori, Dénes Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund’s adjuvant model of orofacial pain |
title | Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund’s adjuvant model of orofacial pain |
title_full | Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund’s adjuvant model of orofacial pain |
title_fullStr | Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund’s adjuvant model of orofacial pain |
title_full_unstemmed | Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund’s adjuvant model of orofacial pain |
title_short | Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund’s adjuvant model of orofacial pain |
title_sort | neurotransmitter and tryptophan metabolite concentration changes in the complete freund’s adjuvant model of orofacial pain |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175490/ https://www.ncbi.nlm.nih.gov/pubmed/32316909 http://dx.doi.org/10.1186/s10194-020-01105-6 |
work_keys_str_mv | AT csehedinak neurotransmitterandtryptophanmetaboliteconcentrationchangesinthecompletefreundsadjuvantmodeloforofacialpain AT veresgabor neurotransmitterandtryptophanmetaboliteconcentrationchangesinthecompletefreundsadjuvantmodeloforofacialpain AT kortesitamas neurotransmitterandtryptophanmetaboliteconcentrationchangesinthecompletefreundsadjuvantmodeloforofacialpain AT polyakhelga neurotransmitterandtryptophanmetaboliteconcentrationchangesinthecompletefreundsadjuvantmodeloforofacialpain AT nanasinikolett neurotransmitterandtryptophanmetaboliteconcentrationchangesinthecompletefreundsadjuvantmodeloforofacialpain AT tajtijanos neurotransmitterandtryptophanmetaboliteconcentrationchangesinthecompletefreundsadjuvantmodeloforofacialpain AT pardutzarpad neurotransmitterandtryptophanmetaboliteconcentrationchangesinthecompletefreundsadjuvantmodeloforofacialpain AT klivenyipeter neurotransmitterandtryptophanmetaboliteconcentrationchangesinthecompletefreundsadjuvantmodeloforofacialpain AT vecseilaszlo neurotransmitterandtryptophanmetaboliteconcentrationchangesinthecompletefreundsadjuvantmodeloforofacialpain AT zadoridenes neurotransmitterandtryptophanmetaboliteconcentrationchangesinthecompletefreundsadjuvantmodeloforofacialpain |